medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 5

<< Back Next >>

Ann Hepatol 2013; 12 (5)

Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine

Qian J, Gang J, Ke-qing S, Hong C, Yi-xin W, Ming-hua Z

Language: English
References: 29
Page: 803-809
PDF size: 158.96 Kb.


ABSTRACT

Objective. To systematically review the effect of Acetyl-L-Carnitine in patients with hepatic encephalopathy. Material and methods. Design: systematic review and meta-analysis. Data sources: The Cochrane Library, MEDLINE, EMBASE.com, Science Citation Index, Google search and the China Biological Medicine Database to June 2012. Review methods: randomized placebo controlled trials of Acetyl-L-Carnitine in patients with hepatic encephalopathy assessing whether Acetyl-L-Carnitine an effective therapy or not. No language restrictions were applied. Two reviewers independently extracted data and assessed quality. Results. 7 methodologically sound randomized controlled trials were identified involving 660 participants with hepatic encephalopathy, totaling 249 with subclinical hepatic encephalopathy, 189 with West Haven grade 1, 162 with West Haven grade 2 and 60 with West Haven grade 3. Acetyl-L-Carnitine was effective to improve serum ammonia level (weighted mean difference 25.90, 95% confidence intervals 20.89 to 30.91, P ‹ 0.05) and the number connection test completion time (weighted mean difference 16.62, 95% confidence intervals 9.88 to 23.36, P ‹ 0.05). The outcome was consistent in subgroup analyses. No publication bias was detected. Adverse events were reported infrequently and were minor. Conclusions. Acetyl-L-Carnitine is promising as an effective and tolerable treatment for hepatic encephalopathy that associated with improved serum ammonia levels and the number connection test.


REFERENCES

  1. Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer TD (eds.). Hepatology: A Textbook of Liver Diseases. Vol 1. 3rd ed. Philadelphia: Saunders; 1996, 605-17.

  2. McPhail MJ, Bajaj JS, Thomas HC, Taylor-Robinson SD. Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010; 4: 365-78.

  3. Blei AT, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic Encephalopathy. Am J Gastroenterol 2001; 96: 1968-76.

  4. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046-51.

  5. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20: 1064-70.

  6. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-Laspartate in the management of hepatic encephalopathy: A meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.

  7. Jiang Q, Jiang G, Welty TE, Zheng M. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther 2010; 35: 333-41.

  8. No authors listed. Acetyl-L-carnitine. Monograph. Altern Med Rev 2010; 15: 76-83.

  9. Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013; 28: 193-9.

  10. Missler J, Zwingmann C. L-carnitine in Hyperammonemia and Hepatic Encephalopathy. Miscellanea on Encephalopathies- A Second Look 2012; 16: 365-90.

  11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9.

  12. Conn HO. Trail making and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.

  13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.

  14. Altman DG, Schulz KF. Statistics notes: concealing treatment allocation in randomized trials. BMJ 2001; 323: 446-7.

  15. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.

  16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.

  17. Cooper JR, Bloom FE, Roth RH. Neuroactive peptides. In: The Biochemical Basis of Neuropharmacology. 6th ed. New York, Oxford: Oxford University Press; 1991; p. 381-427.

  18. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhoais. BMJ 1988; 297: 1501-4.

  19. Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011; 46: 750-9.

  20. Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011; 26: 281-9.

  21. Cecere A, Ciaramella F, Tancredi L, Romano C, Gattoni A. Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial. Clin Drug Investig 2002; 22: 7-14.

  22. Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2011; 93: 799-808.

  23. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008; 53: 3018-25.

  24. Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11: 7197–202.

  25. Malaguarnera M, Pistone G, Astuto M, Dell’Arte S, Finocchiaro G, Lo Giudice E, Pennisi G. L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003; 21: 271-5.

  26. Matsuda I, Ohtani Y, Ohyanagi K, Yamamoto S. Hyperammonemia related to carnitine metabolism with particular emphasis on ornithine transcarbamylase deficiency. Enzyme 1987; 38: 251-5.

  27. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000; 34: 630-8.

  28. Shores NJ, Keeffe EB. Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci 2008; 53: 2330-3.

  29. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 2012; 28: 221-5.




2020     |     www.medigraphic.com